The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants
Open accessAbstract
BACKGROUND: In 2003, severe acute respiratory syndrome coronavirus (SARS-CoV) was identified as the etiological agent of severe acute respiratory syndrome, a disease characterized by severe pneumonia that sometimes results in death. SARS-CoV is a zoonotic virus that crossed the species barrier, most likely originating from bats or from other species including civets, raccoon dogs, domestic cats, swine, and rodents. A SARS-CoV vaccine should confer long-term protection, especially in vulnerable senescent populations, against both the 2003 epidemic strains and zoonotic strains that may yet emerge from animal reservoirs. We report the comprehensive investigation of SARS vaccine efficacy in young and senescent mice following homologous and heterologous challenge. METHODS AND FINDINGS: Using Venezuelan equine encephalitis virus replicon particles (VRP) expressing the 2003 epidemic Urbani SARS-CoV strain spike (S) glycoprotein (VRP-S) or the nucleocapsid (N) protein from the same strain (VRP-N), we demonstrate that VRP-S, but not VRP-N vaccines provide complete short- and long-term protection against homologous strain challenge in young and senescent mice. To test VRP vaccine efficacy against a heterologous SARS-CoV, we used phylogenetic analyses, synthetic biology, and reverse genetics to construct a chimeric virus (icGDO3-S) encoding a synthetic S glycoprotein gene of the most genetically divergent human strain, GDO3, which clusters among the zoonotic SARS-CoV. icGD03-S replicated efficiently in human airway epithelial cells and in the lungs of young and senescent mice, and was highly resistant to neutralization with antisera directed against the Urbani strain. Although VRP-S vaccines provided complete short-term protection against heterologous icGD03-S challenge in young mice, only limited protection was seen in vaccinated senescent animals. VRP-N vaccines not only failed to protect from homologous or heterologous challenge, but resulted in enhanced immunopathology with eosinophilic infiltrates within the lungs of SARS-CoV-challenged mice. VRP-N-induced pathology presented at day 4, peaked around day 7, and persisted through day 14, and was likely mediated by cellular immune responses. CONCLUSIONS: This study identifies gaps and challenges in vaccine design for controlling future SARS-CoV zoonosis, especially in vulnerable elderly populations. The availability of a SARS-CoV virus bearing heterologous S glycoproteins provides a robust challenge inoculum for evaluating vaccine efficacy against zoonotic strains, the most likely source of future outbreaks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MrBayes 3: Bayesian phylogenetic inference under mixed models
Ronquist, F., & Huelsenbeck, J. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/btg180 · Cited by 29,077
MRBAYES: Bayesian inference of phylogenetic trees.
Huelsenbeck, J. P., & Ronquist, F. (2001) · Bioinformatics · doi:10.1093/bioinformatics/17.8.754 · Cited by 21,937
The rapid generation of mutation data matrices from protein sequences
Jones, D. T., Taylor, W. R., & Thornton, J. M. (1992) · Bioinformatics · doi:10.1093/bioinformatics/8.3.275 · Cited by 6,947
Multiple sequence alignment with the Clustal series of programs
Chenna, R. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg500 · Cited by 4,875
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344
Bats Are Natural Reservoirs of SARS-Like Coronaviruses
Li, W., Shi, Z., Yu, M., Ren, W., Smith, C., Epstein, J. H., Wang, H., Crameri, G., Hu, Z., Zhang, H., et al. (2005) · Science · doi:10.1126/science.1118391 · Cited by 2,560
Guan, Y., Zheng, B. J., He, Y. Q., Liu, X. L., Zhuang, Z. X., Cheung, C. L., Luo, S. W., Li, P. H., Zhang, L. J., Guan, Y. J., et al. (2003) · Science · doi:10.1126/science.1087139 · Cited by 2,406
KIM, H. W., CANCHOLA, J. G., BRANDT, C. D., PYLES, G., CHANOCK, R. M., JENSEN, K., & PARROTT, R. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120955 · Cited by 1,981
Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats
Lau, S. K. P., Woo, P. C. Y., Li, K. S. M., Huang, Y., Tsoi, H.-W., Wong, B. H. L., Wong, S. S. Y., Leung, S.-Y., Chan, K.-H., & Yuen, K.-Y. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506735102 · Cited by 1,544
Cello, J., Paul, A. V., & Wimmer, E. (2002) · Science · doi:10.1126/science.1072266 · Cited by 980
Molecular Evolution of the SARS Coronavirus During the Course of the SARS Epidemic in China
The Chinese SARS Molecular Epidemiology Consortium (2004) · Science · doi:10.1126/science.1092002 · Cited by 775
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
Yang, Z.-Y., Kong, W.-P., Huang, Y., Roberts, A., Murphy, B. R., Subbarao, K., & Nabel, G. J. (2004) · Nature · doi:10.1038/nature02463 · Cited by 665
Smith, H. O., Hutchison, C. A., Pfannkoch, C., & Venter, J. C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2237126100 · Cited by 611
Sui, J., Li, W., Murakami, A., Tamin, A., Matthews, L. J., Wong, S. K., Moore, M. J., Tallarico, A. S. C., Olurinde, M., Choe, H., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307140101 · Cited by 550
Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus
Kobasa, D., Takada, A., Shinya, K., Hatta, M., Halfmann, P., Theriault, S., Suzuki, H., Nishimura, H., Mitamura, K., Sugaya, N., et al. (2004) · Nature · doi:10.1038/nature02951 · Cited by 455
Bisht, H., Roberts, A., Vogel, L., Bukreyev, A., Collins, P. L., Murphy, B. R., Subbarao, K., & Moss, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401939101 · Cited by 420
Subbarao, K., McAuliffe, J., Vogel, L., Fahle, G., Fischer, S., Tatti, K., Packard, M., Shieh, W.-J., Zaki, S., & Murphy, B. (2004) · Journal of Virology · doi:10.1128/jvi.78.7.3572-3577.2004 · Cited by 406
Identification of a Novel Coronavirus in Bats
Poon, L. L. M., Chu, D. K. W., Chan, K. H., Wong, O. K., Ellis, T. M., Leung, Y. H. C., Lau, S. K. P., Woo, P. C. Y., Suen, K. Y., Yuen, K. Y., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.4.2001-2009.2005 · Cited by 397
Buchholz, U. J., Bukreyev, A., Yang, L., Lamirande, E. W., Murphy, B. R., Subbarao, K., & Collins, P. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403492101 · Cited by 385
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus
Yount, B., Curtis, K. M., Fritz, E. A., Hensley, L. E., Jahrling, P. B., Prentice, E., Denison, M. R., Geisbert, T. W., & Baric, R. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1735582100 · Cited by 376
Self-citationSims, A. C., Baric, R. S., Yount, B., Burkett, S. E., Collins, P. L., & Pickles, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.24.15511-15524.2005 · Cited by 349
Self-citationWeingartl, H., Czub, M., Czub, S., Neufeld, J., Marszal, P., Gren, J., Smith, G., Jones, S., Proulx, R., Deschambault, Y., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12672-12676.2004 · Cited by 344
Viral Loads in Clinical Specimens and SARS Manifestations
Hung, I. F. N., Cheng, V. C. C., Wu, A. K. L., Tang, B. S. F., Chan, K. H., Chu, C. M., Wong, M. M. L., Hui, W. T., Poon, L. L. M., Tse, D. M. W., et al. (2004) · Emerging Infectious Diseases · doi:10.3201/eid1009.040058 · Cited by 270
Bukreyev, A., Lamirande, E. W., Buchholz, U. J., Vogel, L. N., Elkins, W. R., Claire, M. S., Murphy, B. R., Subbarao, K., & Collins, P. L. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16501-x · Cited by 256
Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses
Yang, Z.-Y., Werner, H. C., Kong, W.-P., Leung, K., Traggiai, E., Lanzavecchia, A., & Nabel, G. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409065102 · Cited by 253
Murasko, D. (2002) · Experimental Gerontology · doi:10.1016/s0531-5565(01)00210-8 · Cited by 248
Immunosenescence and germinal center reaction
Zheng, B., Han, S., Takahashi, Y., & Kelsoe, G. (1997) · Immunological Reviews · doi:10.1111/j.1600-065x.1997.tb01028.x · Cited by 229
Davis, N. L., Caley, I. J., Brown, K. W., Betts, M. R., Irlbeck, D. M., McGrath, K. M., Connell, M. J., Montefiori, D. C., Frelinger, J. A., Swanstrom, R., et al. (2000) · Journal of Virology · doi:10.1128/jvi.74.1.371-378.2000 · Cited by 200
Self-citationRoberts, A., Paddock, C., Vogel, L., Butler, E., Zaki, S., & Subbarao, K. (2005) · Journal of Virology · doi:10.1128/jvi.79.9.5833-5838.2005 · Cited by 198
Risk factors for encephalitis and death from West Nile virus infection
MURRAY, K., BARANIUK, S., RESNICK, M., ARAFAT, R., KILBORN, C., CAIN, K., SHALLENBERGER, R., YORK, T. L., MARTINEZ, D., HELLUMS, J. S., et al. (2006) · Epidemiology and Infection · doi:10.1017/s0950268806006339 · Cited by 197
Initial viral load and the outcomes of SARS
Chu, C.-M. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1040398 · Cited by 196
Chen, Z., Zhang, L., Qin, C., Ba, L., Yi, C. E., Zhang, F., Wei, Q., He, T., Yu, W., Yu, J., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.5.2678-2688.2005 · Cited by 183
Olsen, C. W., Corapi, W. V., Ngichabe, C. K., Baines, J. D., & Scott, F. W. (1992) · Journal of Virology · doi:10.1128/jvi.66.2.956-965.1992 · Cited by 179
Kim, T. W., Lee, J. H., Hung, C.-F., Peng, S., Roden, R., Wang, M.-C., Viscidi, R., Tsai, Y.-C., He, L., Chen, P.-J., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4638-4645.2004 · Cited by 173
Severe Acute Respiratory Syndrome (SARS): A Year in Review
Skowronski, D. M., Astell, C., Brunham, R. C., Low, D. E., Petric, M., Roper, R. L., Talbot, P. J., Tam, T., & Babiuk, L. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.091103.134135 · Cited by 173
The unmet need in the elderly: Designing new influenza vaccines for older adults
McElhaney, J. E. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.04.019 · Cited by 168
LoBue, A. D., Lindesmith, L. C., Yount, B. L., Harrington, P. R., Thompson, J. M., Johnston, R. E., Moe, C. L., & Baric, R. S. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.03.080 · Cited by 161
Self-citationSee, R. H., Zakhartchouk, A. N., Petric, M., Lawrence, D. J., Mok, C. P. Y., Hogan, R. J., Rowe, T., Zitzow, L. A., Karunakaran, K. P., Hitt, M., et al. (2006) · Journal of General Virology · doi:10.1099/vir.0.81579-0 · Cited by 159
Greenough, T. C., Babcock, G. J., Roberts, A., Hernandez, H. J., Thomas, Jr., Coccia, J. A., Graziano, R. F., Srinivasan, M., Lowy, I., Finberg, R. W., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/427242 · Cited by 158
Hancock, G. E., Speelman, D. J., Heers, K. M., Bortell, E., Smith, J. D., & Cosco, C. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.7783-7791.1996 · Cited by 156
Kapadia, S. U., Rose, J. K., Lamirande, E. W., Vogel, L., Subbarao, K., & Roberts, A. (2005) · Virology · doi:10.1016/j.virol.2005.06.016 · Cited by 155
Antibody responses to individual proteins of SARS coronavirus and their neutralization activities
Qiu, M., Shi, Y., Guo, Z., Chen, Z., He, R., Chen, R., Zhou, D., Dai, E., Wang, X., Si, B., et al. (2005) · Microbes and Infection · doi:10.1016/j.micinf.2005.02.006 · Cited by 147
Impaired germinal center reaction in mice with short telomeres
Herrera, E., Martínez‐A, C., & Blasco, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.3.472 · Cited by 144 · cited 1×
“For instance, antibody responses in the immunosenescent tend to offer less protection with limited switching to secondary isotypes, lower antibody levels in general, and production of antibody with lower affinities [69] [70] [71] [72] [73] [74] .”
Frasca, D., Riley, R. L., & Blomberg, B. B. (2005) · Seminars in Immunology · doi:10.1016/j.smim.2005.05.005 · Cited by 134
de Swart, R. L., Kuiken, T., Timmerman, H. H., van Amerongen, G., van den Hoogen, B. G., Vos, H. W., Neijens, H. J., Andeweg, A. C., & Osterhaus, A. D. M. E. (2002) · Journal of Virology · doi:10.1128/jvi.76.22.11561-11569.2002 · Cited by 133
He, Y., Zhou, Y., Siddiqui, P., & Jiang, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.10.052 · Cited by 130
Spruth, M., Kistner, O., Savidis-Dacho, H., Hitter, E., Crowe, B. A., Gerenčer, M., Brühl, P., Grillberger, L., Reiter, M., Tauer, C., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.08.055 · Cited by 121
Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates
Liu, S., Leng, C. H., Lien, S., Chi, H.-Y., HUANG, C., LIN, C., Wu, L., Chen, C., HSIEH, S., & Chong, P. C.-S. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.01.058 · Cited by 120
He, Y., Li, J., Li, W., Lustigman, S., Farzan, M., & Jiang, S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.6085 · Cited by 118
A human SARS-CoV neutralizing antibody against epitope on S2 protein
Duan, J., Yan, X., Guo, X., Cao, W., Han, W., Qi, C., Feng, J., Yang, D., Gao, G., & Jin, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.089 · Cited by 114 · cited 1×
“The GDO3-S glycoprotein contains 17 amino acid changes relative to Urbani-S ( Figure 3B ), many of which map within neutralizing epitopes between amino acids 130-150 and 318-510, part of the receptor binding domain (RBD) [41, [43] [44] [45] [46] [47] [48] [49] [50] .”
Takasuka, N. (2004) · International Immunology · doi:10.1093/intimm/dxh143 · Cited by 113
Age‐related changes in antibody repertoire: contribution from T cells
Song, H., Price, P. W., & Černý, J. (1997) · Immunological Reviews · doi:10.1111/j.1600-065x.1997.tb01027.x · Cited by 108
Is there an ideal animal model for SARS?
Subbarao, K., & Roberts, A. (2006) · Trends in Microbiology · doi:10.1016/j.tim.2006.05.007 · Cited by 104
He, Y., Zhu, Q., Liu, S., Zhou, Y., Baoan, Y., Li, J., & Jiang, S. (2005) · Virology · doi:10.1016/j.virol.2005.01.034 · Cited by 102
Keng, C. T., Zhang, A., Shen, S., Lip, K.-M., Fielding, B. C., Tan, T. H. P., Chou, C.-F., Loh, C. B., Wang, S., Fu, J., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.6.3289-3296.2005 · Cited by 102
An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus
Qin, C., Wang, J., Wei, Q., She, M., Marasco, W. A., Jiang, H., Tu, X., Zhu, H., Ren, L., Gao, H., et al. (2005) · The Journal of Pathology · doi:10.1002/path.1769 · Cited by 96
Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine
Zhu, M. (2004) · Immunology Letters · doi:10.1016/j.imlet.2004.01.001 · Cited by 95
A serological survey on neutralizing antibody titer of SARS convalescent sera
Zhang, J.-S., Chen, J.-T., Liu, Y.-X., Zhang, Z.-S., Gao, H., Liu, Y., Wang, X., Ning, Y., Liu, Y.-F., Gao, Q., et al. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20431 · Cited by 93
Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch
Frech, S. A., Kenney, R. T., Spyr, C., Lazar, H., Viret, J., Herzog, C., Glück, R., & Glenn, G. M. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.06.036 · Cited by 92
Yount, B. L., Roberts, R., Lindesmith, L. C., & Baric, R. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605438103 · Cited by 91
Self-citationAnimal coronavirus vaccines: lessons for SARS.
Saif, L. J. (2004) · PubMed · Cited by 87
Faber, M., Lamirande, E. W., Roberts, A., Papaneri, A. B., Koprowski, H., Dietzschold, B., & Schnell, M. J. (2005) · Journal of General Virology · doi:10.1099/vir.0.80844-0 · Cited by 87
Alphavirus Replicon Particles as Candidate HIV Vaccines
Davis, N., West, A., Reap, E. A., MacDonald, G. H., Collier, M., Dryga, S. A., Maughan, M. F., Connell, M. J., Walker, C., McGrath, K., et al. (2002) · IUBMB Life · doi:10.1080/15216540212657 · Cited by 86
Self-citationWang, S., Chou, T.-H. W., Sakhatskyy, P. V., Huang, S., Lawrence, J. M., Cao, H., Huang, X., & Lu, S. (2005) · Journal of Virology · doi:10.1128/jvi.79.3.1906-1910.2005 · Cited by 80
Immunogenicity of SARS inactivated vaccine in BALB/c mice
Xiong, S., Wang, Y., Zhang, M., Liu, X., Zhang, C., Liu, S., Qian, C.-W., Li, J., Lu, J., Wan, Z.-Y., et al. (2004) · Immunology Letters · doi:10.1016/j.imlet.2004.06.014 · Cited by 70
Johnson, T. R., Varga, S. M., Braciale, T. J., & Graham, B. S. (2004) · Journal of Virology · doi:10.1128/jvi.78.16.8753-8760.2004 · Cited by 69
Mounting Lab Accidents Raise SARS Fears
Normile, D. (2004) · Science · doi:10.1126/science.304.5671.659 · Cited by 68
An overview of serum antibody responses to influenza virus antigens.
Couch, R. B. (2003) · PubMed · Cited by 67
Zakhartchouk, A. N., Liu, Q., Petric, M., & Babiuk, L. A. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.04.011 · Cited by 63
Tripp, R. A., Haynes, L. M., Moore, D. D., Anderson, B. C., Tamin, A., Harcourt, B. H., Jones, L. P., Yilla, M., Babcock, G. J., Greenough, T. C., et al. (2005) · Journal of Virological Methods · doi:10.1016/j.jviromet.2005.03.021 · Cited by 58
Heise, M. T., Simpson, D. A., & Johnston, R. E. (2000) · Journal of Virology · doi:10.1128/jvi.74.9.4207-4213.2000 · Cited by 55
Self-citationWang, Z., Yuan, Z., Matsumoto, M., Hengge, U. R., & Chang, Y.-F. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.147 · Cited by 53
SARS Vaccine Protective in Mice
Stadler, K., Roberts, A., Becker, S., Vogel, L., Eickmann, M., Kolesnikova, L., Klenk, H. D., Murphy, B. R., Rappuoli, R., Abrignani, S., et al. (2005) · Emerging infectious diseases · doi:10.3201/eid1108.041003 · Cited by 47
A follow-up study of 69 discharged SARS patients.
Han, Y., Geng, H., Feng, W., et al. (2003) · PubMed · Cited by 38
DNA Vaccine of SARS-Cov S Gene Induces Antibody Response in Mice
Zhao, P., Ke, J.-S., Qin, Z.-L., Ren, H., Zhao, L.-J., Yu, J.-G., Gao, J., Zhu, S.-Y., & Qi, Z.-T. (2004) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/36.1.37 · Cited by 37
SARS: Retrospective cohort study among German guests of the Hotel 'M', Hong Kong
Radun, D., Niedrig, M., Ammon, A., et al. (2003) · Eurosurveillance · doi:10.2807/esm.08.12.00436-en · Cited by 25
Chou, T.-H. W., Wang, S., Sakhatskyy, P. V., Mboudoudjeck, I., Lawrence, J. M., Huang, S., Coley, S., Baoan, Y., Li, J., Zhu, Q., et al. (2005) · Virology · doi:10.1016/j.virol.2005.01.035 · Cited by 24
SARS Clinical Features, United States, 2003
Srikantiah, P., Charles, M. D., Reagan, S., Clark, T. A., Pletz, M. W., Patel, P. R., Hoekstra, R. M., Lingappa, J. R., Jernigan, J. A., & Fischer, M. (2005) · Emerging infectious diseases · doi:10.3201/eid1101.040585 · Cited by 23
Ishii, K., Hasegawa, H., Nagata, N., Mizutani, T., Morikawa, S., Suzuki, T., Taguchi, F., Tashiro, M., Takemori, T., Miyamura, T., et al. (2006) · Virology · doi:10.1016/j.virol.2006.03.020 · Cited by 21
Cited by
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098
Coronaviruses post-SARS: update on replication and pathogenesis
Perlman, S., & Netland, J. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2147 · Cited by 1,764
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citation
Metadata
- Authors
- Deming, D., Sheahan, T., Heise, M., Yount, B., Davis, N., Sims, A., Suthar, M., Harkema, J., Whitmore, A., Pickles, R., West, A., Donaldson, E., Curtis, K., Johnston, R., & Baric, R.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2006-12-26
- Volume
- 3
- Issue
- 12
- Pages
- e525
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2151847720
- Cited by
- 275
- References
- 80
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.